Insider Selling: Boston Scientific Co. (NYSE:BSX) EVP Sells $539,785.90 in Stock

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $77.30, for a total value of $539,785.90. Following the completion of the transaction, the executive vice president now owns 42,908 shares in the company, valued at approximately $3,316,788.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Wendy Carruthers also recently made the following trade(s):

• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $75.33, for a total value of $526,029.39.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $76.11 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The firm’s 50 day moving average is $75.23 and its two-hundred day moving average is $68.02. The firm has a market capitalization of $111.66 billion, a P/E ratio of 63.96, a PEG ratio of 2.63 and a beta of 0.78. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $77.99.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, beating the consensus estimate of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The firm had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Analysts anticipate that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors have recently bought and sold shares of BSX. First Foundation Advisors bought a new stake in shares of Boston Scientific during the 1st quarter worth about $25,000. Eagle Bay Advisors LLC increased its stake in shares of Boston Scientific by 542.1% during the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares during the period. RiverPark Advisors LLC bought a new stake in Boston Scientific during the first quarter worth approximately $30,000. Northwest Investment Counselors LLC acquired a new stake in Boston Scientific in the first quarter worth approximately $31,000. Finally, YHB Investment Advisors Inc. acquired a new position in shares of Boston Scientific during the 1st quarter valued at $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the subject of a number of recent analyst reports. The Goldman Sachs Group assumed coverage on shares of Boston Scientific in a research report on Thursday, May 30th. They set a “buy” rating and a $90.00 price target for the company. JPMorgan Chase & Co. increased their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lifted their price target on Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research note on Thursday, April 25th. Raymond James upped their price objective on Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research note on Thursday, April 25th. Finally, StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $77.41.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.